Market Report Source

Overview

Report Overview

This report examines the global mood disorder sector and highlights the converging market stimulators and inhibitors that may lead to a market decline from an estimated US$17.4 billion in 2005 to US$15 billion in 2012. Key factors discussed include patent expirations of leading antidepressants over the next 7 years, increased generic substitution trends, safety concerns over SSRIs; cost-containment in prescribing; and litigation activities between research-based and generic companies. Key market stimulators identified to buffer the decline include the introduction of new drug classes, new formulations, line extensions, increased patient populations, and treatment resistance. The report also evaluates the emerging market sector of cognitive and memory impairment and shows the extent of R&D activities within the field. Analysis of both sectors reveals candidates that have top-line earning prospects and also provides an insight into potential licensing or acquisition opportunities in promising psychopharmacotherapy market subsectors.

Table of Contents

CONTENTS
List of Tables
List of Figures
Executive Summary
Objectives of the Report
Research Methodology

Chapter 1 Introduction to Mood Disorders and Cognitive Impairment
Depression
Prevalence
Aetiology of Depression
Types of Depression
Major depression
Dysthymia
Bipolar Disorder
Symptoms of Depression
Anxiety Disorders
Prevalence
Cognitive Impairments and Memory Deficits
Prevalence
Pharmacotherapy for Cognitive Impairment

Chapter 2 The Global Market for Mood Disorders: Depression and Anxiety
Mood Disorders: Depression and Anxiety
Market Overview of Drugs to Treat Depression and Anxiety Disorders
Market Analysis and Insights for Drugs to Treat Depressive Illnesses
Market Analysis: Antidepressant Therapy Area
Prozac (Fluoxetine) – Eli Lilly
Product Overview
Indications and Supplementary Labelling
Patent Expiry and Reformulation
Sales Prospects
Commercial Outlook
Cymbalta (Duloxetine) – Eli Lilly/Boehringer Ingelheim
Product Overview
Indications and Supplementary Labelling
Sales Prospects
Commercial Outlook
Zoloft/Lustral (Sertraline) – Pfizer
Product Overview
Indications and Supplementary Labelling
Patent Expiry and Reformulation
Sales Prospects
Commercial Outlook
Seroxat/Paxil/Deroxat (Paroxetine) – GlaxoSmithKline
Product Overview
Indications and Supplementary Labelling
Patent Expiry and Reformulation
Sales Prospects
Commercial Outlook
Wellbutrin (Bupropion) – GlaxoSmithKline
Product Overview
Indications and Supplementary Labelling
Patent Expiry and Reformulation
Sales Prospects
Commercial Outlook
Effexor (Venlafaxine) – Wyeth
Product Overview
Indications and Supplementary Labelling
Patent Expiry and Reformulation
Sales Prospects
Commercial Outlook
Remeron/Zispin (Mirtazapine) – Organon/Akzo Nobel
Product Overview
Indications and Supplementary Labelling
Patent Expiry and Reformulation
Sales Prospects
Commercial Outlook
Cipramil/Celexa (Citalopram) – Lundbeck/Forest Laboratories
Product Overview
Indications and Supplementary Labelling
Patent Expiry and Reformulation
Sales Prospects
Commercial Outlook
Cipralex/Lexapro (Escitalopram) – Lundbeck/Forest
Product Overview
Indications and Supplementary Labelling
Patent Expiry and Reformulation
Sales Prospects
Commercial Outlook
Future Considerations and Market Insights for the Antidepressant Market
Pipeline Antidepressants
Pipeline Focus
Valdoxan (Agomelatine) – Servier
Pharmacotherapeutics for Cognitive Impairment and /Memory Deficits
Future Market Focus – Age-Related Cognitive Decline
Nootropil (Piracetam) – UCB Pharma
Companies Developing Drugs for Cognitive and Memory Impairment
EGb 761/Tanakan – Ipsen

Chapter 3 Drugs in Research and Development
Pipeline Mood Stabilizers and Drugs for Cognitive Impairment
Drugs in Development for Mood Disorders: Antidepressants and Anxiolytics
Depression and Anxiety: Research and Development Overview
Drugs in Development for Cognitive and Memory Impairment
Cognitive/Memory Impairment – Research and Development Overview

Chapter 4 Market Analysis, Therapy Forecasting, and Prospect Mining
Data Analysis, Therapy Forecasting, and Prospect Mining
Market Analysis and Therapy Forecasting
Antidepressants and Anxiolytics
Therapy Area Forecasts
Comparative Analysis: Antidepressant/Anxiolytic Product Sales
Prospect Mining
Mood Disorders: Depression and Anxiety
Cognitive and Memory Impairment
Therapy Area Forecasts, 2012 and 2020

Chapter 5 Report Synopsis
Depressive/Anxiety and Cognitive/Memory Impairment – Key Data Points

Bibliography and Reference Sources

List of Tables
Table 1.1 Role of Neurotransmitters in Depression
Table 1.2 Symptoms of Depression and Bipolar Disorder/Mania
Table 1.3 Major Anxiety Disorders
Table 1.4 Causes of Dementia
Table 2.1 Estimated Global Sales & Forecasts of Leading Antidepressants, 2004-2012 (US$m)
Table 2.2 Estimated Annual Growth Rates of Leading Antidepressants (%), 2004-2012
Table 2.3 Leading Antidepressants Ranked by Sales, 2005 & 2012
Table 2.4 Primary and Secondary Indications for Antidepressants
Table 2.5 Estimated Sales (US$) and Annual Growth (%) of Prozac, 2005-2012
Table 2.6 Estimated Sales (US$) and Annual Growth (%) of Cymbalta, 2005-2012
Table 2.7 Estimated Sales (US$) and Annual Growth (%) of Zoloft, 2005-2012
Table 2.8 Estimated Sales (US$) and Annual Growth (%) of Seroxat/Paxil, 2005-2012
Table 2.9 Estimated Sales (US$) and Annual Growth (%) of Wellbutrin, 2005-2012
Table 2.10 Estimated Sales (US$) and Annual Growth (%) of Effexor, 2005-2012
Table 2.11 Estimated Sales (US$) and Annual Growth (%) of Remeron, 2005-2012
Table 2.12 Estimated Sales (US$) and Annual Growth (%) of Cipramil/Celexa, 2005-12
Table 2.13 Estimated Sales (US$) and Annual Growth (%) of Cipralex/Lexapro, 2005-12
Table 2.14 Drugs in Development for Cognitive and Memory Impairment, 2005 (partial)
Table 3.1 Drugs in Development for Depression and Anxiety, 2005
Table 3.2 Drugs in Development for Cognitive and Memory Impairment, 2005
Table 4.1 Global Drug Market for Antidepressants and Anxiolytics (US$m) 2004-2012
Table 4.2 Therapy Area Forecasts for the Global Mood Disorders and Cognitive Impairment Market Sectors, 2012 and 2020

List of Figures
Figure 2.1 Estimated Global Sales of Leading Antidepressants, 2005 & 2012
Figure 2.2 Estimated Market Share of Leading Antidepressants, 2005 & 2012
Figure 4.1 Therapy Area Forecasts for Antidepressants and Anxiolytics, 2005 & 2012 (US$m)
Figure 4.2 Comparative Analysis of Leading Antidepressants and Anxiolytics 2004-2012
Figure 4.3 Key Antidepressant/Anxiolytic Prospects in the CNS Development Pipeline, 2005
Figure 4.4 Key Cognitive and Memory Impairment Prospects in the CNS Development Pipeline, 2005